Navigation Links
Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc.
Date:1/16/2008

Agreement Provides for Provider Services, Inc. to fund $600,000 for Product Development Associated with the Ready-To-Drink Product to be Developed by

Millennium pursuant to the terms of the $20,000,000 5-year Purchase

Agreement

BASKING RIDGE, N.J., Jan. 16 /PRNewswire/ -- Millennium Biotechnologies Inc., wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) today announced that it will receive $600,000 in funding pursuant to the terms of a one year Product Development Agreement with Provider Services, Inc. of Cleveland, Ohio (PSI). As Ohio's second largest services provider for the Long Term Care channel, with sales in excess of 300 million dollars, PSI will provide services to over 12,000 residents in 2008.

"Our agreement will allow us to use Millennium's extensive clinical experience and success in the cancer and HIV channels and apply that experience to the nutritional challenges in the Long Term Care channel," stated Mark Mirken, President and Chief Operating Officer of Millennium Biotechnologies.

"Expanding our relationship with MBI and MBTG by funding the product development and providing PSI a one year lead to market on products they provide will give us a significant cost savings and market advantage," Brian Colleran, CEO of PSI stated. Mr. Colleran added, "This will continue to allow us enhance the quality of life for our residents and new tenants."

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support p
'/>"/>

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference
2. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
3. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
4. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
7. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
8. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
9. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
10. Speaking of Womens Health Community Event Returns to All Wal-Mart Supercenters Nationwide January 12th
11. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in orde
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
...sychologists have found in a study that instead of...how one feels about their body shape and thereby a...ies the way they are end up with the lowest body m...ology and one of the researchers said that eating ...
...abeling mix-up among about 135 people, whose blood...d to a re-test among 90 people as one of the patie...test in April. The pathology center has conc...hs without knowing it. The mix-up was reveal...
...o assess the economic impact of air quality change...re found to be second only to timber losses in ter...ished in the Canadian Journal of Forest Research, ...imates the effects in terms of health risk to be b...
... in mice has found that though they do not develop...ty researchers were able to differentiate the cell...or the oily skin. The research examines how a seba...t Rockefeller University, settles this argument, s...
...ity Improvement Scotland (QIS) review of the perfo... in 2003 for food, fluid and nutritional care find... The NHS Quality Improvement Scotland had iss...dmitted following concerns about the number of und...
...essive amounts of soda and sugary drinks is making...iew.// Frank Hu and his colleagues at the Har...dible scientific nutrition studies conducted over ...erages account for half of those calories, reporte...
Other Medicine News:Health News:Study Finds Healthier Women Are Those Who Accept The Way They Look 2Health News:'Blimp1' Gene Linked To Oily Skin 2
(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/3/2009)ACTON, Mass., Dec. 3 Allen Medical Systems, a subsidiary of Hill-Rom Holdings, Inc. (NYSE: HRC ), today announced the launch of its new Allen Amatech(TM) OEM (Original Equipment Manufacturer) busin
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Many Hospitals Are Not Ready for H1N1 3A Nurse Survey Shows Deficiencies in Hospital Swine Flu Readiness 55369 1Many Hospitals Are Not Ready for H1N1 3A Nurse Survey Shows Deficiencies in Hospital Swine Flu Readiness 55369 2Many Hospitals Are Not Ready for H1N1 3A Nurse Survey Shows Deficiencies in Hospital Swine Flu Readiness 55369 3Top Newport Beach Plastic Surgeon Appointed President of Orange County Society of Plastic Surgeons 55366 1Top Newport Beach Plastic Surgeon Appointed President of Orange County Society of Plastic Surgeons 55366 2eMindful Offers Employers Complete Set of Wellness Tools Partnership with Online Health Coaching Service Rounds Out Health Package 55361 1eMindful Offers Employers Complete Set of Wellness Tools Partnership with Online Health Coaching Service Rounds Out Health Package 55361 2eMindful Offers Employers Complete Set of Wellness Tools Partnership with Online Health Coaching Service Rounds Out Health Package 55361 3
...sponse Network (LRN), the national laboratory syst...ergencies, will mark its first decade at its natio..., , Founded in 1999 by the Association of Public ...e Control and Prevention (CDC) and the Federal Bur...ioterrorism, the Laboratory Response Network has e...
.... (Nasdaq: ARNA ) today announced it will hold a...2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ...vioral modification and Lorcaserin for Overweight ...trials evaluating the safety and efficacy of lorca...and Chief Executive Officer, Dominic P. Behan, Ph....
Other Medicine Technology:Nation's Laboratory Response Network Marks First Decade of Protecting Public Health 2Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results 2Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results 3
5F Infiniti
Softtouch
CT Micro Stereotactic System
Tapered Tefcor Movable Core Wire Guides
Medicine Products: